Shattuck Labs, Inc. (STTK) NASDAQ
6.42
+0.17(+2.72%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.42
+0.17(+2.72%)
Currency In USD
| Previous Close | 6.25 |
| Open | 6.17 |
| Day High | 6.5 |
| Day Low | 6.06 |
| 52-Week High | 6.81 |
| 52-Week Low | 0.69 |
| Volume | 417,659 |
| Average Volume | 676,440 |
| Market Cap | 307.54M |
| PE | -9.17 |
| EPS | -0.7 |
| Moving Average 50 Days | 4.89 |
| Moving Average 200 Days | 2.71 |
| Change | 0.17 |
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 1:00 PM GMT
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antib
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
GlobeNewswire Inc.
Feb 06, 2026 1:30 PM GMT
AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily re
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 15, 2025 9:15 PM GMT
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (